Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Metallopolymers Protect Penicillin-Like Antibiotics from Bacterial Beta-Lactamase

By LabMedica International staff writers
Posted on 12 May 2014
Novel drug combinations that unite classical penicillin-like antibiotics with metallopolymers effectively kill bacteria, including "superbugs" such as MRSA (methicillin-resistant Staphylococcus aureus) that had developed beta-lactamase enzyme-based resistance to the antibiotics.

Metallopolymers are a class of polymers with metal atoms either in the backbone or at the side chain. More...
These polymers exhibit many unprecedented properties and functions that conventional organic polymers usually lack. Among metallopolymers, metallocene-containing polymers have attracted significant attention due to their unique electrochemical, catalytic, and optical properties. Metallocene-containing polymers are widely used for redox active systems as recognition of ions and sugars and modification of electrodes.

MRSA, a complex of multi-drug-resistant Gram-positive bacterial strains, has proven especially problematic in both hospital and community settings by deactivating conventional beta-lactam antibiotics, including penicillins, cephalosporins, and carbapenems, through various mechanisms, resulting in increased mortality rates and hospitalization costs.

To correct this problem, investigators at the University of South Carolina (Columbia, USA) developed an improved class of beta-lactam antibiotics by conjugating classical penicillin-like antibiotics to cobaltocenium metallopolymers.

They reported in the March 17, 2014, online edition of the Journal of the American Chemical Society that these combinations exhibited a synergistic effect against MRSA by efficiently inhibiting activity of beta-lactamase and effectively lysing bacterial cells. Various conventional beta-lactam antibiotics, including penicillin-G, amoxicillin, ampicillin, and cefazolin, were protected from beta-lactamase hydrolysis via the formation of unique ion-pairs between their carboxylate anions and cationic cobaltocenium moieties.

"Instead of developing new antibiotics, here we ask the question, "Can we recycle the old antibiotics"? With traditional antibiotics like penicillin G, amoxicillin, ampicillin, and so on, can we give them new life"? In the United States every year, around 100,000 patients die of bacteria-induced infections," said senior author Dr. Chuanbing Tang, professor of chemistry and biochemistry at the University of South Carolina. "And the problem is increasing because bacteria are building resistance. It is a really, really big problem, not only for individual patients, but also for society."

Related Links:

University of South Carolina



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.